Literature DB >> 12044298

Treatment failure in intestinal strongyloidiasis: an indicator of HTLV-I infection.

Angelica Terashima1, Humberto Alvarez, Raúl Tello, Rosa Infante, David O Freedman, Eduardo Gotuzzo.   

Abstract

BACKGROUND: The association of severe strongyloides with HTLV-I is well known; however, the seroprevalence of HTLV-I in other groups with strongyloidiasis is still unknown. We conducted a prospective study in patients with intestinal strongyloidiasis without known immunodepression who failed to respond to standard therapy with ivermectin or thiabendazole (failure was defined as one positive stool examination at the post-therapy follow up). All these patients were tested for HTLV-I by ELISA and Western Blot.
RESULTS: Forty seven patients were evaluated: 74.5% (35 out of 47) were HTLV-I positive, without significant difference between males (76%) and females (72.7%).
CONCLUSIONS: We recommend that all patients with uncomplicated intestinal strongyloidiasis, who fail standard therapy, be studied for HTLV-I infection.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12044298     DOI: 10.1016/s1201-9712(02)90132-3

Source DB:  PubMed          Journal:  Int J Infect Dis        ISSN: 1201-9712            Impact factor:   3.623


  14 in total

1.  Non-oral treatment with ivermectin for disseminated strongyloidiasis.

Authors:  Dahlene N Fusco; Jennifer A Downs; Michael J Satlin; Meera Pahuja; Liz Ramos; Philip S Barie; Lawrence Fleckenstein; Henry W Murray
Journal:  Am J Trop Med Hyg       Date:  2010-10       Impact factor: 2.345

Review 2.  Strongyloides stercoralis hyperinfection syndrome: a deeper understanding of a neglected disease.

Authors:  George Vasquez-Rios; Roberto Pineda-Reyes; Juan Pineda-Reyes; Ricardo Marin; Eloy F Ruiz; Angélica Terashima
Journal:  J Parasit Dis       Date:  2019-02-06

Review 3.  Parasitic central nervous system infections in immunocompromised hosts.

Authors:  Melanie Walker; Joseph R Zunt
Journal:  Clin Infect Dis       Date:  2005-03-02       Impact factor: 9.079

4.  Update on strongyloidiasis in the immunocompromised host.

Authors:  Luis A Marcos; Angélica Terashima; Marco Canales; Eduardo Gotuzzo
Journal:  Curr Infect Dis Rep       Date:  2011-02       Impact factor: 3.725

5.  Case Report: Incidentally Discovered Strongyloides stercoralis Infection after Urinary Diversion.

Authors:  Ajay Bhasin; Emily Yura; Darren Boyd; Linda Kuksuk; John P Flaherty
Journal:  Am J Trop Med Hyg       Date:  2020-06       Impact factor: 2.345

6.  Treatment of strongyloidiasis in HTLV-1 and Strongyloides stercoralis coinfected patients is associated with increased TNFα and decreased soluble IL2 receptor levels.

Authors:  Fernanda Salles; Andrea Bacellar; Mirla Amorim; Glória Orge; Michael Sundberg; Márcia Lima; Silvane Santos; Aurélia Porto; Edgar Carvalho
Journal:  Trans R Soc Trop Med Hyg       Date:  2013-08       Impact factor: 2.184

7.  Clinical associations of Human T-Lymphotropic Virus type 1 infection in an indigenous Australian population.

Authors:  Lloyd Einsiedel; Tim Spelman; Emma Goeman; Olivier Cassar; Mick Arundell; Antoine Gessain
Journal:  PLoS Negl Trop Dis       Date:  2014-01-16

8.  A Rare Case of Strongyloides Hyperinfection from Hypogammaglobulinemia.

Authors:  Paidi Ramakrishna Reddy; Sujith M Thomas; A Rajalakshmi; Deepak Vijayan; Muraleedharan Raman
Journal:  Indian J Crit Care Med       Date:  2017-07

9.  Strongyloidiasis and infective dermatitis alter human T lymphotropic virus-1 clonality in vivo.

Authors:  Nicolas A Gillet; Lucy Cook; Daniel J Laydon; Carol Hlela; Kristien Verdonck; Carolina Alvarez; Eduardo Gotuzzo; Daniel Clark; Lourdes Farré; Achiléa Bittencourt; Becca Asquith; Graham P Taylor; Charles R M Bangham
Journal:  PLoS Pathog       Date:  2013-04-04       Impact factor: 6.823

10.  High prevalence of Strongyloides stercoralis infection among the elderly in Brazil.

Authors:  Maria Margarida Naves; Julia Maria Costa-Cruz
Journal:  Rev Inst Med Trop Sao Paulo       Date:  2013 Sep-Oct       Impact factor: 1.846

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.